On October 14, 2020 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that a Trial in Progress abstract for CI-8993, a first-in-class monoclonal anti-VISTA antibody, has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting, which will be held virtually from November 9-14, 2020 (Press release, Curis, OCT 14, 2020, View Source [SID1234568481]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster session are as follows:
Title: Phase 1 Study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies
Author: Melissa L. Johnson, MD, Sarah Cannon Research Institute
Date & Time: Wednesday, November 11th, 2020 – Saturday, November 14th, 2020 from 9:00 am – 5:00 pm ET
Abstract ID: 743
Additional meeting information can be found on the SITC (Free SITC Whitepaper) website at www.sitcancer.org. The poster presentation will also be available under "Events and Presentations" in the Investors section of the Company’s website at www.curis.com